Literature DB >> 11872253

GPI1046 prevents dopaminergic dysfunction by activating glutathione system in the mouse striatum.

Ken-ichi Tanaka1, Michiyo Yoshioka, Ikuko Miyazaki, Naoko Fujita, Norio Ogawa.   

Abstract

We investigated both the antioxidant activities of GPI1046, a non-immunosuppressive derivative of FK506, and the in vivo neuroprotective properties against toxicity of intracerebroventricular 6-hydroxydopamine (6-OHDA) in mice. The 6-OHDA-induced reduction in dopamine and its metabolites in the striatum was significantly normalized by daily administration of GPI1046. Moreover, GPI1046 significantly reduced lipid peroxidation in vivo. Further, GPI1046 significantly increased striatal glutathione (GSH) levels by activating GSH synthesis, although the striatal catalase and superoxide dismutase activities did not change. We conclude that GPI1046 may have neuroprotective effects both in cell cultures and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872253     DOI: 10.1016/s0304-3940(01)02547-2

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Candidate genes and their regulatory elements: alcohol preference and tolerance.

Authors:  Laura Saba; Sanjiv V Bhave; Nicholas Grahame; Paula Bice; Razvan Lapadat; John Belknap; Paula L Hoffman; Boris Tabakoff
Journal:  Mamm Genome       Date:  2006-06-12       Impact factor: 2.957

Review 2.  Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

Authors:  Amaal AlDakheel; Lorraine V Kalia; Anthony E Lang
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Neurodegeneration and neuroprotection in Parkinson disease.

Authors:  Stanley Fahn; David Sulzer
Journal:  NeuroRx       Date:  2004-01

4.  Neuroimmunophilin GPI-1046 reduces ethanol consumption in part through activation of GLT1 in alcohol-preferring rats.

Authors:  Y Sari; S N Sreemantula
Journal:  Neuroscience       Date:  2012-10-08       Impact factor: 3.590

5.  Neuroimmunophilin ligands protect cavernous nerves after crush injury in the rat: new experimental paradigms.

Authors:  Heather Valentine; Yi Chen; Hongzhi Guo; Jocelyn McCormick; Yong Wu; Sena F Sezen; Ahmet Hoke; Arthur L Burnett; Joseph P Steiner
Journal:  Eur Urol       Date:  2006-11-16       Impact factor: 20.096

6.  Molecular basis of anti-apoptotic effect of immunophilin ligands on hydrogen peroxide-induced apoptosis in human glioma cells.

Authors:  Ken-ichi Tanaka; Masato Asanuma; Norio Ogawa
Journal:  Neurochem Res       Date:  2004-08       Impact factor: 3.996

Review 7.  Role of immunophilins in recovery of erectile function after cavernous nerve injury.

Authors:  Sena F Sezen; Gwen Lagoda; Arthur L Burnett
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 8.  Targets for neuroprotection in Parkinson's disease.

Authors:  Talene A Yacoubian; David G Standaert
Journal:  Biochim Biophys Acta       Date:  2008-10-01

Review 9.  Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse.

Authors:  Sade Spencer; Peter W Kalivas
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.